Phenotypes of prediabetes and stratification of cardiometabolic risk.

Prediabetes is associated with increased risks of type 2 diabetes, cardiovascular disease, dementia, and cancer, and its prevalence is increasing worldwide. Lifestyle and pharmacological interventions in people with prediabetes can prevent the development of diabetes and possibly cardiovascular disease. However, prediabetes is a highly heterogeneous metabolic state, both with respect to its pathogenesis and prediction of disease. Improved understanding of these features and precise phenotyping of prediabetes could help to improve stratification of disease risk. In this Personal View, we focus on the extreme metabolic phenotypes of metabolically healthy obesity and metabolically unhealthy normal weight, insulin secretion failure, insulin resistance, visceral obesity, and non-alcoholic fatty liver disease. We present new analyses aimed at improving characterisation of phenotypes in lean, overweight, and obese people with prediabetes. We discuss evidence from lifestyle intervention studies to explore whether these phenotypes can also be used for individualised prediction and prevention of cardiometabolic diseases.

[1]  N. Stefan,et al.  The role of hepatokines in metabolism , 2013, Nature Reviews Endocrinology.

[2]  Bo Zhang,et al.  The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study , 2008, The Lancet.

[3]  Johanna Kuusisto,et al.  Changes in Insulin Sensitivity and Insulin Release in Relation to Glycemia and Glucose Tolerance in 6,414 Finnish Men , 2009, Diabetes.

[4]  E. Ferrannini,et al.  Plasma glucose levels as predictors of diabetes: the Mexico City diabetes study , 2009, Diabetologia.

[5]  J. Gallacher,et al.  Glycated hemoglobin measurement and prediction of cardiovascular disease. , 2014, JAMA.

[6]  N. Stefan,et al.  The Metabolically Benign and Malignant Fatty Liver , 2011, Diabetes.

[7]  M. Kivimäki,et al.  Trajectories of cardiometabolic risk factors before diagnosis of three subtypes of type 2 diabetes: a post-hoc analysis of the longitudinal Whitehall II cohort study. , 2013, The lancet. Diabetes & endocrinology.

[8]  T. Gill,et al.  Diabetes and Cardiovascular Disease Outcomes in the Metabolically Healthy Obese Phenotype , 2013, Diabetes Care.

[9]  E. Ravussin,et al.  Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians. , 1993, The New England journal of medicine.

[10]  Dan J Stein,et al.  Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013 , 2015, BDJ.

[11]  T. Lauritzen,et al.  Relationship between insulin resistance and β-cell dysfunction in subphenotypes of prediabetes and type 2 diabetes. , 2015, The Journal of clinical endocrinology and metabolism.

[12]  M. Schulze Determinants for the Effectiveness of Lifestyle Intervention in the Finnish Diabetes Prevention Study , 2008, Diabetes Care.

[13]  S. Kahn,et al.  Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future , 2014, The Lancet.

[14]  Ashutosh Kumar Singh,et al.  Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015 , 2016, Lancet.

[15]  M. Kivimaki,et al.  The natural course of healthy obesity over 20 years. , 2015, Journal of the American College of Cardiology.

[16]  Guang Ning,et al.  Diabetes in China: a societal solution for a personal challenge. , 2014, The lancet. Diabetes & endocrinology.

[17]  K. Reynolds,et al.  The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999-2004). , 2008, Archives of internal medicine.

[18]  Remi Rabasa-Lhoret,et al.  Metabolic and body composition factors in subgroups of obesity: what do we know? , 2004, The Journal of clinical endocrinology and metabolism.

[19]  Wolfgang Rathmann,et al.  Prediabetes: a high-risk state for diabetes development , 2012, The Lancet.

[20]  J. Kielstein,et al.  Glucose levels and risk of dementia. , 2013, The New England journal of medicine.

[21]  S. Yusuf,et al.  Basal insulin glargine and microvascular outcomes in dysglycaemic individuals: results of the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial , 2014, Diabetologia.

[22]  T. Assimes,et al.  Detailed Physiologic Characterization Reveals Diverse Mechanisms for Novel Genetic Loci Regulating Glucose and Insulin Metabolism in Humans , 2010, Diabetes.

[23]  Lars Bäckman,et al.  Accelerated Progression From Mild Cognitive Impairment to Dementia in People With Diabetes , 2010, Alzheimer's & Dementia.

[24]  T. Valle,et al.  Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. , 2001, The New England journal of medicine.

[25]  G. Shulman Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease. , 2014, The New England journal of medicine.

[26]  Xiaohui Guo,et al.  Risk of non-fatal cardiovascular diseases in early-onset versus late-onset type 2 diabetes in China: a cross-sectional study. , 2016, The lancet. Diabetes & endocrinology.

[27]  L. Geiss,et al.  Prevalence of and Trends in Diabetes Among Adults in the United States, 1988-2012. , 2015, JAMA.

[28]  B. Zinman,et al.  Are Metabolically Healthy Overweight and Obesity Benign Conditions? , 2013, Annals of Internal Medicine.

[29]  E. Ingelsson,et al.  Insulin Sensitivity Measured With Euglycemic Clamp Is Independently Associated With Glomerular Filtration Rate in a Community-Based Cohort , 2008, Diabetes Care.

[30]  L. Bouter,et al.  Intra-individual variation of glucose, specific insulin and proinsulin concentrations measured by two oral glucose tolerance tests in a general Caucasian population: the Hoorn Study , 1996, Diabetologia.

[31]  G. Roglić,et al.  Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23-year follow-up study. , 2014, The lancet. Diabetes & endocrinology.

[32]  M. Pollak The insulin and insulin-like growth factor receptor family in neoplasia: an update , 2012, Nature Reviews Cancer.

[33]  Jaakko Tuomilehto,et al.  Determinants for the Effectiveness of Lifestyle Intervention in the Finnish Diabetes Prevention Study , 2008, Diabetes Care.

[34]  C. Bogardus,et al.  The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. , 1999, The Journal of clinical investigation.

[35]  M. Kivimäki,et al.  Midlife type 2 diabetes and poor glycaemic control as risk factors for cognitive decline in early old age: a post-hoc analysis of the Whitehall II cohort study , 2014, The lancet. Diabetes & endocrinology.

[36]  G. Hotamisligil,et al.  Inflammation and metabolic disorders , 2006, Nature.

[37]  J. Olefsky,et al.  The cellular and signaling networks linking the immune system and metabolism in disease , 2012, Nature Medicine.

[38]  S. Kwak,et al.  10-year trajectory of β-cell function and insulin sensitivity in the development of type 2 diabetes: a community-based prospective cohort study. , 2016, The lancet. Diabetes & endocrinology.

[39]  J. Shaw,et al.  Diabetes: a 21st century challenge. , 2014, The lancet. Diabetes & endocrinology.

[40]  J. Lindström,et al.  Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study , 2006, The Lancet.

[41]  David M Nathan,et al.  10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. , 2009, Lancet.

[42]  Salim Yusuf,et al.  Basal insulin and cardiovascular and other outcomes in dysglycemia. , 2012, The New England journal of medicine.

[43]  S. Sharp,et al.  Definitions of Metabolic Health and Risk of Future Type 2 Diabetes in BMI Categories: A Systematic Review and Network Meta-analysis , 2015, Diabetes Care.

[44]  Peter Almgren,et al.  Clinical risk factors, DNA variants, and the development of type 2 diabetes. , 2008, The New England journal of medicine.

[45]  K. Watson,et al.  Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study , 2012, The Lancet.

[46]  S. Yusuf,et al.  Effects of basal insulin glargine and omega-3 fatty acid on cognitive decline and probable cognitive impairment in people with dysglycaemia: a substudy of the ORIGIN trial. , 2014, The lancet. Diabetes & endocrinology.

[47]  T. Hansen,et al.  Natural History of Insulin Sensitivity and Insulin Secretion in the Progression From Normal Glucose Tolerance to Impaired Fasting Glycemia and Impaired Glucose Tolerance: The Inter99 Study , 2009, Diabetes Care.

[48]  L. Luzi,et al.  Prevalence, Metabolic Features, and Prognosis of Metabolically Healthy Obese Italian Individuals , 2010, Diabetes Care.

[49]  Z. Halpern,et al.  Non‐alcoholic fatty liver disease independently predicts prediabetes during a 7‐year prospective follow‐up , 2013, Liver international : official journal of the International Association for the Study of the Liver.

[50]  F. Schick,et al.  A high-risk phenotype associates with reduced improvement in glycaemia during a lifestyle intervention in prediabetes , 2015, Diabetologia.

[51]  O. Franco,et al.  Lifetime risk of developing impaired glucose metabolism and eventual progression from prediabetes to type 2 diabetes: a prospective cohort study. , 2016, The lancet. Diabetes & endocrinology.

[52]  D. Mozaffarian,et al.  Interventions to Promote Physical Activity and Dietary Lifestyle Changes for Cardiovascular Risk Factor Reduction in Adults A Scientific Statement From the American Heart Association Endorsed by the Preventive Cardiovascular Nurses Association and the Society of Behavioral Medicine , 2010 .

[53]  N. Stefan,et al.  Circulating fetuin-A and free fatty acids interact to predict insulin resistance in humans , 2013, Nature Medicine.

[54]  C. Snehalatha,et al.  Classification and Diagnosis of Diabetes , 2016 .

[55]  W. Knowler,et al.  Regression From Pre-Diabetes to Normal Glucose Regulation in the Diabetes Prevention Program , 2009, Diabetes Care.

[56]  M. Laakso,et al.  Cardiovascular Disease in Type 2 Diabetes From Population to Man to Mechanisms , 2010, Diabetes Care.

[57]  H. Yki-Järvinen Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. , 2014, The lancet. Diabetes & endocrinology.

[58]  Fritz Schick,et al.  Identification and characterization of metabolically benign obesity in humans. , 2008, Archives of internal medicine.

[59]  J. Shaw,et al.  Global estimates of diabetes prevalence for 2013 and projections for 2035. , 2014, Diabetes Research and Clinical Practice.

[60]  Ralph A. DeFronzo,et al.  From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus , 2009, Diabetes.

[61]  L. Groop,et al.  Fasting Versus Postload Plasma Glucose Concentration and the Risk for Future Type 2 Diabetes , 2009, Diabetes Care.

[62]  S. Yusuf,et al.  Effect of Insulin Glargine and n-3FA on Carotid Intima-Media Thickness in People With Dysglycemia at High Risk for Cardiovascular Events , 2013, Diabetes Care.

[63]  S. Fowler,et al.  Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. , 2002 .

[64]  N. Stefan,et al.  Inhibition of 11β-HSD1 with RO5093151 for non-alcoholic fatty liver disease: a multicentre, randomised, double-blind, placebo-controlled trial. , 2014, The lancet. Diabetes & endocrinology.

[65]  K. Chien,et al.  Blood glucose concentration and risk of pancreatic cancer: systematic review and dose-response meta-analysis , 2016, British Medical Journal.

[66]  Tracey McLaughlin,et al.  Heterogeneity in the prevalence of risk factors for cardiovascular disease and type 2 diabetes mellitus in obese individuals: effect of differences in insulin sensitivity. , 2007, Archives of internal medicine.

[67]  Dan J Stein,et al.  Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013 , 2015, BDJ.

[68]  Peisong Chen,et al.  Prediabetes and the risk of cancer: a meta-analysis , 2014, Diabetologia.

[69]  Devjit Tripathy,et al.  Pioglitazone for diabetes prevention in impaired glucose tolerance. , 2011, The New England journal of medicine.

[70]  D. Eizirik,et al.  ER Stress in Pancreatic β Cells: The Thin Red Line Between Adaptation and Failure , 2010, Science Signaling.

[71]  BOULIN,et al.  Classification and Diagnosis of Diabetes. , 2022, Primary care.

[72]  André Rodrigues,et al.  Mellitus , 2018, Proceedings of the 17th International Conference on Mobile and Ubiquitous Multimedia.

[73]  M. Blüher,et al.  Are metabolically healthy obese individuals really healthy? , 2014, European journal of endocrinology.

[74]  E. Ravussin,et al.  Metabolically healthy and unhealthy obese – the 2013 Stock Conference report , 2014, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[75]  Vilmundur Gudnason,et al.  Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death , 2011 .

[76]  Kristine Faerch,et al.  Heterogeneity of Pre-diabetes and Type 2 Diabetes: Implications for Prediction, Prevention and Treatment Responsiveness. , 2015, Current diabetes reviews.

[77]  C. Mantzoros,et al.  Metabolic health and weight: Understanding metabolically unhealthy normal weight or metabolically healthy obese patients. , 2016, Metabolism: clinical and experimental.

[78]  K. Cusi,et al.  Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. , 2012, Gastroenterology.

[79]  F. Hu,et al.  Metabolically healthy obesity: epidemiology, mechanisms, and clinical implications. , 2013, The lancet. Diabetes & endocrinology.

[80]  Cynthia Balion,et al.  Annual incidence and relative risk of diabetes in people with various categories of dysglycemia: a systematic overview and meta-analysis of prospective studies. , 2007, Diabetes research and clinical practice.

[81]  S. Minoshima,et al.  Insulin resistance and Alzheimer-like reductions in regional cerebral glucose metabolism for cognitively normal adults with prediabetes or early type 2 diabetes. , 2011, Archives of neurology.

[82]  F. Schick,et al.  Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. , 2009, Journal of hepatology.

[83]  C. Herder,et al.  The IL-1 Pathway in Type 2 Diabetes and Cardiovascular Complications , 2015, Trends in Endocrinology & Metabolism.

[84]  T. Hansen,et al.  Insulin sensitivity, insulin release and glucagon-like peptide-1 levels in persons with impaired fasting glucose and/or impaired glucose tolerance in the EUGENE2 study , 2008, Diabetologia.

[85]  Mika Kivimäki,et al.  Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study , 2009, The Lancet.

[86]  M. Kivimäki,et al.  Incidence of Metabolic Risk Factors Among Healthy Obese Adults , 2015, Journal of the American College of Cardiology.

[87]  M. Roizen,et al.  10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study , 2010 .

[88]  E. Ferrannini Definition of intervention points in prediabetes. , 2014, The lancet. Diabetes & endocrinology.

[89]  C. Kahn,et al.  Insulin signalling and the regulation of glucose and lipid metabolism , 2001, Nature.

[90]  M. Albert,et al.  Diabetes in Midlife and Cognitive Change Over 20 Years , 2014, Annals of Internal Medicine.

[91]  Bruce M. Spiegelman,et al.  What We Talk About When We Talk About Fat , 2014, Cell.

[92]  P. Scherer,et al.  Adiponectin: mechanistic insights and clinical implications , 2012, Diabetologia.

[93]  M. Laakso,et al.  Effect of nateglinide on the incidence of diabetes and cardiovascular events. , 2010, The New England journal of medicine.

[94]  M. McCarthy,et al.  Common Genetic Variants Highlight the Role of Insulin Resistance and Body Fat Distribution in Type 2 Diabetes, Independent of Obesity , 2014, Diabetes.

[95]  D. Leroith,et al.  Mechanisms of Disease: metabolic effects of growth hormone and insulin-like growth factor 1 , 2007, Nature Clinical Practice Endocrinology &Metabolism.

[96]  D. Harnois,et al.  Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease , 2011 .

[97]  R. DeFronzo,et al.  Pathophysiologic Approach to Therapy in Patients With Newly Diagnosed Type 2 Diabetes , 2013, Diabetes Care.

[98]  Norbert Stefan,et al.  Causes and metabolic consequences of Fatty liver. , 2008, Endocrine reviews.

[99]  B. Howard,et al.  Effects of Diet and Exercise in Preventing NIDDM in People With Impaired Glucose Tolerance: The Da Qing IGT and Diabetes Study , 1997, Diabetes Care.

[100]  A. Khera,et al.  Dysfunctional adiposity and the risk of prediabetes and type 2 diabetes in obese adults. , 2012, JAMA.